Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
AbstractBackground Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).Objectives To assess the effectiveness and safety of upadacitinib through 48 weeks in real-world clinical practice for Jap...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Libro |
| Publicado: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
| Materias: | |
| Acceso en línea: | Connect to this object online. |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Internet
Connect to this object online.3rd Floor Main Library
| Número de Clasificación: |
A1234.567 |
|---|---|
| Copia 1 | Disponible |